Eli Lilly Stock - Weekly review and sector comparison for big pharma

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:05 UTC. Details in the imprint.

Eli Lilly and Company (US5324571083) remains one of the most highly valued names in global pharmaceuticals. The stock has consolidated modestly this week after a strong multi-month rally, while investors reassess valuations against peers based on recent earnings and guidance.

How Eli Lilly performed this week

Based on delayed composite data, Eli Lilly shares recently changed hands around $1,112.00, implying a daily move of roughly -0.9% in the latest regular session. A price overview from WallStreetNumbers shows the stock modestly lower on the day but still sharply higher year-on-year.

Over the past 12 months, Eli Lilly stock has gained more than 40%, far outpacing many large pharmaceutical peers that generally delivered single-digit to low double-digit returns over the same period. Market data compiled by Arincen also highlight a market capitalization approaching $1 trillion, underscoring investor optimism about the company’s pipeline and growth prospects.

Sector comparison and valuations

Eli Lilly currently trades on a trailing price-earnings multiple near the high-30s to low-40s, while many diversified pharma peers in the US and Europe change hands at mid-teens to low-20s earnings multiples. Consensus data on Investing.com show the valuation premium as investors price in faster growth.

With a market capitalization reported around $1.0 trillion, Eli Lilly sits in a different league from most drug makers, many of which are valued below $300 billion. Against this backdrop, even small revisions to growth expectations can have a meaningful impact on sentiment across the sector.

What recent earnings showed

At the end of April, Eli Lilly reported first-quarter 2026 results that comfortably beat consensus estimates. The company delivered earnings per share of about $8.55 versus expectations near $6.97, and revenue around $19.8 billion, according to compiled estimates.

This beat reinforced the growth narrative that has driven the stock and contributed to its valuation premium. Analysts now project continued double-digit revenue growth for the current year, supported by key diabetes and obesity treatments as well as other pipeline assets.

How the company makes money

Eli Lilly’s business is centered on branded prescription medicines, with a strong focus on diabetes, obesity, immunology, oncology and neuroscience. Blockbuster diabetes and weight-management therapies such as tirzepatide-based products are currently key growth drivers and account for a large share of revenue momentum.

Where the stock trades today

The shares of Eli Lilly and Company (US5324571083) trade on the New York Stock Exchange at $1,112.00 as of 06/18/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.